Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jessie K. Kennedy"'
Autor:
Matthew H. Collins, Gail E. Potter, Matt D. T. Hitchings, Ellie Butler, Michelle Wiles, Jessie K. Kennedy, Sofia B. Pinto, Adla B. M. Teixeira, Arnau Casanovas-Massana, Nadine G. Rouphael, Gregory A. Deye, Cameron P. Simmons, Luciano A. Moreira, Mauricio L. Nogueira, Derek A. T. Cummings, Albert I. Ko, Mauro M. Teixeira, Srilatha Edupuganti
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-18 (2022)
Abstract Background Arboviruses transmitted by Aedes aegypti including dengue, Zika, and chikungunya are a major global health problem, with over 2.5 billion at risk for dengue alone. There are no licensed antivirals for these infections, and safe an
Externí odkaz:
https://doaj.org/article/0c7cb17970af479fbfbf807c9dc1e7f4
Autor:
Drissa Coulibaly, Abdoulaye K. Kone, Karim Traore, Amadou Niangaly, Bourema Kouriba, Charles Arama, Amatigue Zeguime, Amagana Dolo, Kirsten E. Lyke, Christopher V. Plowe, Yonas Abebe, Gail E. Potter, Jessie K. Kennedy, Shirley M. Galbiati, Effie Nomicos, Gregory A. Deye, Thomas L. Richie, Eric R. James, Natasha KC, B. Kim Lee Sim, Stephen L. Hoffman, Ogobara K. Doumbo, Mahamadou A. Thera, Matthew B. Laurens
Publikováno v:
EClinicalMedicine, Vol 52, Iss , Pp 101579- (2022)
Summary: Background: Plasmodium falciparum (Pf) Sporozoite (SPZ) Chemoprophylaxis Vaccine (PfSPZ-CVac) involves concurrently administering infectious PfSPZ and malaria drug, often chloroquine (CQ), to kill liver-emerging parasites. PfSPZ-CVac (CQ) pr
Externí odkaz:
https://doaj.org/article/aae8b87f13cf4d72be5ab4f5d3602223
Autor:
David J Diemert, Rodrigo Correa-Oliveira, Carlo Geraldo Fraga, Frederico Talles, Marcella Rezende Silva, Shital M Patel, Shirley Galbiati, Jessie K Kennedy, Jordan S Lundeen, Maria Flavia Gazzinelli, Guangzhao Li, Lara Hoeweler, Gregory A Deye, Maria Elena Bottazzi, Peter J Hotez, Hana M El Sahly, Wendy A Keitel, Jeffrey Bethony, Robert L Atmar
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 17, Iss 3, p e0011236 (2023)
BackgroundRecombinant Schistosoma mansoni Tetraspanin-2 formulated on Alhydrogel (Sm-TSP-2/Alhydrogel) is being developed to prevent intestinal and hepatic disease caused by S. mansoni. The tegumentary Sm-TSP-2 antigen was selected based on its uniqu
Externí odkaz:
https://doaj.org/article/be96f1829afd483789795737d1949860
Autor:
Shirley Galbiati, Jessie K. Kennedy, Thomas L. Richie, Stephen L. Hoffman, Natasha Kc, Lisa A. Jackson, Sumana Chakravarty, Eric R. James, Yonas Abebe, B. Kim Lee Sim, James G. Kublin, Sean C. Murphy, Kristen W. Cohen, Gregory A. Deye
Publikováno v:
PLoS Pathogens, Vol 17, Iss 5, p e1009594 (2021)
PLoS Pathogens
PLoS Pathogens
PfSPZ-CVac combines ‘PfSPZ Challenge’, which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x104 PfSPZ-CVac given 28
Autor:
Gail E Potter, Betty Kim Lee Sim, Anusha Gunasekera, Stephen L. Hoffman, Tao Li, Thomas L. Richie, Matthew Adams, Anita Manoj, Christopher V. Plowe, Tooba Murshedkar, Matthew B. Laurens, Andrea A. Berry, Kirsten E. Lyke, Gregory A. Deye, Yonas Abebe, Biraj Shrestha, Jessie K. Kennedy, Abraham G. Eappen, Kathy A. Strauss, Mark A. Travassos
Publikováno v:
J Infect Dis
Direct venous inoculation of 3.2 × 103 aseptic, purified, cryopreserved, vialed Plasmodium falciparum (Pf) strain NF54 sporozoites, PfSPZ Challenge (NF54), has been used for controlled human malaria infection (CHMI) in the United States, 4 European
Autor:
Priscilla Mvula, Lufina Tsirizani, Jaya Goswami, Rhoda Masonga, Atis Muehlenbachs, Jessie K. Kennedy, Titus H. Divala, Maxwell Kanjala, Osward M. Nyirenda, Blair J. Wylie, Lughano Ndovie, Sarah Boudova, Miriam K. Laufer, Yamikani Mbilizi, Patricia Mawindo, Randy G. Mungwira, Gail E Potter, Masiye John Ndaferankhande, Francis Muwalo, Tamiwe Tomoka
Publikováno v:
The Lancet Infectious Diseases. 18:1097-1107
BACKGROUND: Sulfadoxine-pyrimethamine resistance threatens efficacy of intermittent preventive treatment of malaria during pregnancy, and alternative regimens need to be identified. With the return of chloroquine efficacy in southern Africa, we postu
Autor:
Robert H. Gilman, Gregory A. Deye, Ellen E. Codd, Jessie K. Kennedy, John R. Horton, Thanh Bach, Guohua An, Effie Y.H. Nomicos, Shirley Galbiati, Patricia L. Winokur, Armando E. Gonzalez, Hector H. Garcia
Publikováno v:
Antimicrob Agents Chemother
Neurocysticercosis and trichuriasis are difficult-to-treat parasitic infections that affect more than 1.5 billion people worldwide. Oxfendazole, a potent broad-spectrum benzimidazole anthelmintic approved for use in veterinary medicine, has shown sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc2e6022857de1793d07ea5c2f73df0b
https://europepmc.org/articles/PMC7577123/
https://europepmc.org/articles/PMC7577123/
Autor:
Thomas Conrad, Thanh Bach, Jessie K. Kennedy, Armando E. Gonzalez, Larissa V. Stebounova, Hector H. Garcia, Kiran Gajurel, Daryl J. Murry, Greg Deye, Patricia L. Winokur, Walt Jones, Denice M. Hodgson-Zingman, John R. Horton, Ellen E. Codd, Effie Y.H. Nomicos, Guohua An, Robert H. Gilman, Dilek Ince
Cysticercosis is a parasitic disease that frequently involves the human central nervous system (CNS), and current treatment options are limited. Oxfendazole, a veterinary medicine belonging to the benzimidazole family of anthelmintic drugs, has demon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2f203b7c43ba03e0341087ee72baa34
https://hdl.handle.net/20.500.12866/7396
https://hdl.handle.net/20.500.12866/7396
Autor:
Sean C Murphy, Gregory A Deye, B Kim Lee Sim, Shirley Galbiati, Jessie K Kennedy, Kristen W Cohen, Sumana Chakravarty, Natasha Kc, Yonas Abebe, Eric R James, James G Kublin, Stephen L Hoffman, Thomas L Richie, Lisa A Jackson
Publikováno v:
PLoS Pathogens, Vol 17, Iss 5, p e1009594 (2021)
PfSPZ-CVac combines 'PfSPZ Challenge', which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x104 PfSPZ-CVac given 28 days
Externí odkaz:
https://doaj.org/article/38a4f864bb53428093ed8cf2eb54e63e